Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
de Truchis
P
P
Mathez
D
D
Force
G
G
Rouveix
E
E
Khuong
M A
MA
Chemlal
K
K
Thiaux
C
C
Leibowitch
J
J
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D004279:DNA, Viral / Q000032:analysis; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D000099227:Abacavir
D019380:Anti-HIV Agents; D004279:DNA, Viral; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir